			  UNITED STATES OF AMERICA

		        DEPARTMENT OF TRANSPORTATION

			  OFFICE OF THE SECRETARY

			          WASHINGTON, D.C.

Issued by the Department of Transportation on February 6, 2004

NOTICE OF ACTION TAKEN -- DOCKETS OST-2003-16784

________________________________________________________________________
__________________________________________

This serves as notice to the public of the action described below, taken
by the Department official indicated (no additional confirming order
will be issued in this matter).

Applicant:  Arkia Israeli Airlines, Ltd.				Date Filed:  December 22,
2003

Relief requested:  Exemption from 49 U.S.C. § 41301 to engage in
charter foreign air transportation of persons, property and mail between
any point or points in Israel, on the one hand, and any point or points
in the United States, on the other hand, either directly or via
intermediate points, and beyond for the carriage of stopover or
transiting traffic only.

If renewal, date and citation of last action:  New authority

Applicant representative:  Pierre Murphy<PHONE_NUMBER>

DOT Analyst:  Gordon H. Bingham<PHONE_NUMBER>

Responsive pleadings:  None filed

DISPOSITION

Action:  Approved							Action date:  February 6, 2004

Effective dates of authority granted:  February 6, 2004-February 6, 2005

Basis for approval (bilateral agreement/reciprocity):  Bilateral
aviation agreement between the United States and Israel

Except to the extent exempted/waived, this authority is subject to the
terms, conditions, and limitations indicated:  X  Standard exemption
conditions (attached)

Special conditions/Partial grant/Denial basis/Remarks:  Based on the
record in this case, we found that Arkia is financially and
operationally qualified to perform the services authorized above.  We
also found that Arkia is substantially owned and effectively controlled
by citizens of Israel.  In addition, all of Arkia’s directors and key
management personnel are citizens of Israel.  The carrier is properly
licensed and designated by the Government of Israel to perform the
proposed services.  By memorandum dated January 30, 2004, the FAA
advised us that it knew of no reason why we should act unfavorably on
Arkia’s application.

Action taken by:   Paul L. Gretch, Director

		      Office of International Aviation

________________________________________________________________________
_________

Under authority assigned by the Department in its regulations, 14 CFR
Part 385, we found that (1) the applicant was qualified to perform the
proposed operations; (2) our action was consistent with Department
policy; (3) grant of the authority was consistent with the public
interest; and (4) grant of the authority would not constitute a major
regulatory action under the Energy Policy and Conservation Act of 1975.
To the

extent not granted/deferred/dismissed, we denied all requests in the
referenced Docket.  We may amend, modify, or revoke the authority
granted in this Notice at any time without hearing at our discretion.

Persons entitled to petition the Department for review of the action set
forth in this Notice under the Department’s regulations, 14 CFR §
385.30, may file their petitions within seven (7) days after the date of
issuance of this Notice.  This action was effective when taken, and the
filing of a petition for review will not alter such effectiveness.

An electronic version of this document is available on the World Wide
Web at:

http://dms.dot.gov//reports/reports_aviation.asp

				Attachment

Foreign Carrier Conditions

In the conduct of the operations authorized, the foreign carrier
applicant(s) shall:

(1)  Not conduct any operations unless it holds a currently effective
authorization from its homeland for such operations, and it has filed a
copy of such authorization with the Department;

(2)  Comply with all applicable requirements of the Federal Aviation
Administration, including, but not limited to, 14 CFR Parts 129, 91, and
36, and with all applicable U.S. Government requirements concerning
security.  To assure compliance with all applicable U.S. Government
requirements concerning security, the holder shall, before commencing
any new service (including charter flights) from a foreign airport that
would be the holder’s last point of departure for the United States,
contact its Principal Security Inspector (PSI) to advise the PSI of its
plans and to find out whether the Transportation Security Administration
has determined that security is adequate to allow such airport(s) to be
served;

(3)  Comply with the requirements for minimum insurance coverage
contained in 14 CFR Part 205, and, prior to the commencement of any
operations under this authority, file evidence of such coverage, in the
form of a completed OST Form 6411, with the Federal Aviation
Administration’s Program Management Branch (AFS-260), Flight Standards
Service (any changes to, or termination of, insurance also shall be
filed with that office);

(4)  Not operate aircraft under this authority unless it complies with
operational safety requirements at least equivalent to Annex 6 of the
Chicago Convention;

(5)  Conform to the airworthiness and airman competency requirements of
its Government for international air services;

(6)  Except as specifically exempted or otherwise provided for in a
Department Order, comply with the requirements of 14 CFR Part 203,
concerning waiver of Warsaw Convention liability limits and defenses;

(7)  Agree that operations under this authority constitute a waiver of
sovereign immunity, for the purposes of 28 U.S.C. 1605(a), but only with
respect to those actions or proceedings instituted against it in any
court or other tribunal in the United States that are: (a)  based on its
operations in international air transportation that, according to the
contract of carriage, include a point in the United States as a point of
origin, point of destination, or agreed stopping place, or for which the
contract of carriage was purchased in the United States; or (b)  based
on a claim under any international agreement or treaty cognizable in any
court or other tribunal of the United States.  In this condition, the
term "international air transportation" means "international
transportation" as defined by the Warsaw Convention, except that all
States shall be considered to be High Contracting Parties for the
purpose of this definition;

(8)  Except as specifically authorized by the Department, originate or
terminate all flights to/from the United States in its homeland;

(9)  Comply with the requirements of 14 CFR Part 217, concerning the
reporting of scheduled, nonscheduled, and charter data;

(10) If charter operations are authorized, except as otherwise provided
in the applicable aviation agreement, comply with the Department's rules
governing charters (including 14 CFR Parts 212 and 380); and

(11) Comply with such other reasonable terms, conditions, and
limitations required by the public interest as may be prescribed by the
Department, with all applicable orders or regulations of other U.S.
agencies and courts, and with all applicable laws of the United States.

This authority shall not be effective during any period when the holder
is not in compliance with the conditions imposed above.  Moreover, this
authority cannot be sold or otherwise transferred without explicit
Department approval under Title 49 of the U.S. Code.


[Federal Register Volume 76, Number 210 (Monday, October 31, 2011)]
[Notices]
[Page 67161]
[FR Doc No: 2011-28049]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings

    Take notice that the Commission has received the following Natural
Gas Pipeline Rate and Refund Report filings:

Filings Instituting Proceedings

    Docket Numbers: RP12-36-000.
    Applicants: Northwest Pipeline GP.
    Description: Northwest Pipeline GP submits tariff filing per
154.204: Puget Sound Contract No. 100313--Non-Conforming to be
effective 11/28/2011.
    Filed Date: 10/24/2011.
    Accession Number: 20111024-5057.
    Comment Date: 5 p.m. Eastern Time on Monday, November 07, 2011.

    Docket Numbers: RP12-37-000.
    Applicants: Northern Natural Gas Company.
    Description: Northern Natural Gas Company submits tariff filing per
154.204: 20111007 Essar Non-Conforming to be effective 11/24/2011.
    Filed Date: 10/24/2011.
    Accession Number: 20111024-5068.
    Comment Date: 5 p.m. Eastern Time on Monday, November 07, 2011.

    Docket Numbers: RP12-38-000.
    Applicants: Texas Eastern Transmission, LP.
    Description: Texas Eastern Transmission, LP submits tariff filing
per 154.403: PCB TETLP DEC 2011 FILING to be effective 12/1/2011.
    Filed Date: 10/24/2011.
    Accession Number: 20111024-5084.
    Comment Date: 5 p.m. Eastern Time on Monday, November 07, 2011.

    Docket Numbers: RP12-39-000.
    Applicants: Algonquin Gas Transmission, LLC.
    Description: Algonquin Gas Transmission, LLC submits tariff filing
per 154.403(d)(2): AGT FRQ 2011 FILING to be effective 12/1/2011.
    Filed Date: 10/24/2011.
    Accession Number: 20111024-5097.
    Comment Date: 5 p.m. Eastern Time on Monday, November 07, 2011.

    Docket Numbers: RP12-40-000.
    Applicants: American Midstream (AlaTenn), LLC.
    Description: American Midstream (AlaTenn), LLC submits tariff
filing per 154.204: AlaTenn Negotiated Rate Filing to be effective 11/
25/2011.
    Filed Date: 10/25/2011.
    Accession Number: 20111025-5028.
    Comment Date: 5 p.m. Eastern Time on Monday, November 07, 2011.

    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, and service can be found at:
http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other
information, call<PHONE_NUMBER> (toll free). For TTY, call (202) 502-
8659.

    Dated: October 25, 2011.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2011-28049 Filed 10-28-11; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register: March 26, 2008 (Volume 73, Number 59)]
[Notices]
[Page 16023-16024]
[DOCID:fr26mr08-80]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 1, 2008, from 8:30
a.m. to 5:30 p.m. and on May 2, 2008, from 8:30 a.m. to 4 p.m.
    Location: Hilton Hotel, Washington DC/Rockville Executive Meeting
Center, 1750 Rockville Pike, Rockville, MD 20852.
    Contact Person: Donald W. Jehn or Pearline K. Muckelvene, Center
for Biologics Evaluation and Research (CBER), Food and Drug
Administration, 1401 Rockville Pike (HFM-71), Rockville, MD 20852, 301-
827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area), code<PHONE_NUMBER>. Please call
the Information Line for up-to-date information on this meeting. A
notice in the Federal Register about last minute modifications that
impact a previously announced advisory committee meeting cannot always
be published quickly enough to provide timely notice. Therefore, you
should always check the agency's Web site and call the appropriate
advisory committee hot line/phone line to learn about possible
modifications before coming to the meeting.
    Agenda: On the morning of May 1, 2008, the committee will hear
updates on the following: (1) Summaries of August 22-23, 2007, and
January 9-10, 2008, meetings of the Department of Health and Human
Services Advisory Committee on Blood Safety and Availability; (2) 2007
West Nile Virus Epidemiology and the use of nucleic acid tests to
reduce the risk of transmission of West Nile Virus in Whole Blood and
blood components for transfusion and Human Cells, Tissues, and Cellular
and Tissue-based products (HCT/Ps); (3) implementation of blood donor
screening for infection with Trypanosoma cruzi and the use of
serological tests to reduce the risk of transmission of T. cruzi
infection in Whole Blood and blood components for transfusion and HCT/
Ps; (4) FDA's proposal to lower the minimum recommended lot release
titer for measles antibodies in Immune Globulin Intravenous (Human) and
Immune Globulin Subcutaneous (Human); (5) Gambro/Fenwal Post Approval
Surveillance Study of Platelet Outcomes, Release Tested (PASSPORT) Post
Marketing Study--7 Day Platelets; (6) Experience with 7 Day Platelets
Versus 5 Day Platelets; and (7) FDA Perspective on the PASSPORT Study.
These updates will be followed by informational presentations on FDA's
Center for Biologics Evaluation and Research Safety Teams related to
blood and tissue. In the afternoon, the committee will discuss the
Biomedical Excellence for Safer Transfusion Committee Report on red
blood cell recovery standards. On the morning of May 2, 2008, the
committee will discuss Lev Pharmaceutical's plasma-derived C1 esterase
inhibitor (CINRYZE). Then, in the afternoon the committee will review
the research programs in the Laboratory of Hepatitis and Related
Emerging Agents, Division of Emerging and Transfusion Transmitted
Diseases, Office of Blood Research and Review, CBER Site Visit of
November 8, 2007.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on
the year 2008 and scroll down to the appropriate advisory committee
link.
    Procedure: The entire day of May 1, 2008, and on May 2, 2008, from
8:30 a.m. to 3:15 p.m., the meeting is open to the public. Interested
persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made
to the contact person on or before April 23, 2008. Oral presentations
from the public will be scheduled between approximately 11:50 a.m. and
12:20 p.m. and between approximately 4:20 p.m. and 4:50 p.m. on May 1,
2008, and between approximately 10:40 a.m. and 11:10 a.m. and 2:40 p.m.
and 3 p.m. on May 2, 2008. Those desiring to make formal oral
presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before April 15, 2008. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by April 16,
2008.
    Closed Committee Deliberations: On May 2, 2008, between 3:15 p.m.
and 4 p.m., the meeting will be closed to permit discussion where
disclosure would constitute a clearly unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of
intramural research programs and make recommendations regarding
personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised
that the

agency is not responsible for providing access to electrical outlets.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Donald W. Jehn or
Pearline K. Muckelvene at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/
default.htm for procedures on public conduct during advisory committee
meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: March 20, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-6208 Filed 3-25-08; 8:45 am]

BILLING CODE 4160-01-S